Comparing New Surgical Interventions for BPH: Re-intervention Rates and Clinical Durability

What is it about?

The study aimed to assess the re-intervention rates of new surgical interventions for benign prostatic hyperplasia (BPH). A critical review was performed on PubMed, the Cochrane Library, and Embase databases between May 2010 and December 2022. The study included 32 studies with a total of 2400 participants. The results showed that the re-intervention rates with these new BPH interventions were comparable to transurethral resection of the prostate (TURP) in the short term. However, further studies are required to directly compare these various BPH procedures. The study concluded that these new surgical interventions remain an important factor for consideration when choosing one form of surgical intervention over another novel therapy.

Featured Image

Why is it important?

This research is important as it provides a critical review of new surgical interventions for BPH, which are less invasive in nature, preserve male sexual function, and have relatively quicker recovery compared to conventional TURP. The study aims to determine the re-intervention rates of these new surgical interventions and compare them with conventional TURP. The findings of this study will be useful for clinicians in making informed decisions regarding the best surgical procedure for patients with BPH. Key Takeaways: 1. The re-intervention rates at 12 months for Aquablation, Rezum, iTIND, and PAE were 0.01%, 0.02%, 0.03%, and 0.05%, respectively. 2. The best-ranked treatment at 12 months was transurethral resection of the prostate (TURP), followed by Aquablation, iTIND, Rezum, and UroLift. 3. While the re-intervention rates with these new surgical BPH interventions appear to be comparable to TURP in the short term, further studies are required to directly compare these various BPH procedures.